A phase II study of Velcade (bortezomib, PS-341) and rituximab in relapsed/refractory mantle cell and follicular non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 11 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 11 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.